Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVO CervoMed	$8.44 -5.2%	$8.63	$1.80 ▼ $25.67	$73.89M	-0.23	1.33 million shs	279,078 shs
OVID Ovid Therapeutics	$0.29 -1.3%	$0.35	$0.24 ▼ $3.43	$20.63M	0.27	458,311 shs	306,406 shs
SNTI Senti Biosciences	$3.35 +1.2%	$3.48	$1.52 ▼ $16.94	$87.35M	2.31	804,891 shs	22,626 shs
TCRX TScan Therapeutics	$1.29 -6.9%	$1.49	$1.02 ▼ $9.69	$71.87M	1.06	362,468 shs	244,572 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVO CervoMed	-5.17%	-17.66%	-4.52%	+281.90%	-65.40%
OVID Ovid Therapeutics	-1.33%	-10.35%	+4.05%	-56.70%	-90.61%
SNTI Senti Biosciences	+1.21%	+0.90%	+7.03%	-19.28%	-16.19%
TCRX TScan Therapeutics	-6.55%	-19.69%	+7.08%	-41.06%	-83.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVO CervoMed	3.3606 of 5 stars	4.4	4.0	0.0	1.9	1.7	0.6
OVID Ovid Therapeutics	4.2181 of 5 stars	3.5	4.0	4.6	1.1	2.5	0.6
SNTI Senti Biosciences	2.5442 of 5 stars	3.5	3.0	0.0	2.3	0.8	1.3
TCRX TScan Therapeutics	3.3779 of 5 stars	4.5	4.0	0.0	1.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVO CervoMed	2.89	Moderate Buy	$27.50	225.83% Upside
OVID Ovid Therapeutics	3.00	Buy	$3.03	945.62% Upside
SNTI Senti Biosciences	3.00	Buy	$12.00	258.21% Upside
TCRX TScan Therapeutics	3.00	Buy	$8.50	561.48% Upside

Current Analyst Ratings Breakdown

Latest OVID, CRVO, SNTI, and TCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/6/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
5/2/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
4/24/2025	OVID Ovid Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/8/2025	TCRX TScan Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/26/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/24/2025	OVID Ovid Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
3/18/2025	CRVO CervoMed	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
3/18/2025	CRVO CervoMed	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $21.00
3/17/2025	CRVO CervoMed	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/14/2025	TCRX TScan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$10.00

(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVO CervoMed	$7.14M	10.29	N/A	N/A	$1.30 per share	6.49
OVID Ovid Therapeutics	$566K	36.45	N/A	N/A	$1.24 per share	0.23
SNTI Senti Biosciences	$2.56M	34.12	N/A	N/A	$15.02 per share	0.22
TCRX TScan Therapeutics	$4.42M	16.45	N/A	N/A	$3.15 per share	0.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVO CervoMed	-$2.17M	-$2.03	N/A	N/A	N/A	-118.68%	-44.11%	-39.81%	5/13/2025 (Estimated)
OVID Ovid Therapeutics	-$52.34M	-$0.38	N/A	N/A	N/A	-5,142.56%	-39.24%	-26.19%	5/13/2025 (Estimated)
SNTI Senti Biosciences	-$71.06M	-$12.03	N/A	N/A	N/A	N/A	-154.84%	-77.42%	N/A
TCRX TScan Therapeutics	-$89.22M	-$1.09	N/A	N/A	N/A	-1,188.88%	-58.72%	-36.02%	5/12/2025 (Estimated)

Latest OVID, CRVO, SNTI, and TCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CRVO CervoMed	-$0.60	N/A	N/A	N/A	$1.70 million	N/A
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	N/A	N/A	N/A	$0.03 million	N/A
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/6/2025	Q1 2025	SNTI Senti Biosciences	-$0.56	-$1.41	-$0.85	-$1.41	$1.30 million	$1.30 million
3/20/2025	Q4 2024	SNTI Senti Biosciences	-$3.13	-$0.67	+$2.46	-$0.67	$2.80 million	$5.86 million
3/17/2025	Q4 2024	CRVO CervoMed	-$0.67	-$0.80	-$0.13	-$0.80	$1.51 million	$2.16 million
3/11/2025	Q4 2024	OVID Ovid Therapeutics	-$0.16	-$0.13	+$0.03	-$0.13	$0.19 million	$0.08 million
3/5/2025	Q4 2024	TCRX TScan Therapeutics	-$0.27	-$0.29	-$0.02	-$0.30	$1.43 million	$0.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVO CervoMed	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVO CervoMed	N/A	15.04	15.04
OVID Ovid Therapeutics	0.18	5.66	5.66
SNTI Senti Biosciences	N/A	1.92	1.92
TCRX TScan Therapeutics	0.13	9.56	9.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVO CervoMed	25.15%
OVID Ovid Therapeutics	72.24%
SNTI Senti Biosciences	25.73%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
CRVO CervoMed	36.30%
OVID Ovid Therapeutics	13.30%
SNTI Senti Biosciences	10.70%
TCRX TScan Therapeutics	2.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVO CervoMed	4	8.70 million	3.93 million	Not Optionable
OVID Ovid Therapeutics	60	71.11 million	61.57 million	Optionable
SNTI Senti Biosciences	4	26.07 million	4.30 million	Not Optionable
TCRX TScan Therapeutics	100	56.59 million	51.90 million	Not Optionable

OVID, CRVO, SNTI, and TCRX Headlines

Recent News About These Companies

Research Analysts Issue Forecasts for TCRX Q1 Earnings

May 10 at 9:12 AM | marketbeat.com

What Analysts Are Saying About TScan Therapeutics Stock

May 10 at 12:52 AM | nasdaq.com

HC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock Price

May 9 at 8:33 AM | marketbeat.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

May 8 at 12:59 PM | marketbeat.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7 at 1:00 PM | benzinga.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

May 7 at 8:45 AM | marketbeat.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $9.33 Consensus PT from Brokerages

May 6, 2025 | americanbankingnews.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from Analysts

May 5, 2025 | marketbeat.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

Adage Capital Partners GP L.L.C. Trims Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

April 30, 2025 | marketbeat.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%

April 17, 2025 | aaii.com

TScan Therapeutics (NASDAQ:TCRX) Earns Buy Rating from Needham & Company LLC

April 10, 2025 | marketbeat.com

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

April 9, 2025 | markets.businessinsider.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 17.27%

April 8, 2025 | aaii.com

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025 | globenewswire.com

TScan Therapeutics appoints Camiolo as SVP, Market Access

March 27, 2025 | markets.businessinsider.com

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

March 27, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 10.92%

March 18, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
3 High-Yield Dividend Stocks Trading at a Discount
By Nathan Reiff | April 14, 2025
View 3 High-Yield Dividend Stocks Trading at a Discount
3 Safe Dividend Stocks as Investors Seek to Reset Diversification
By Chris Markoch | April 14, 2025
View 3 Safe Dividend Stocks as Investors Seek to Reset Diversification
GE Aerospace: Analysts Say New Highs Are Coming
By Thomas Hughes | April 24, 2025
View GE Aerospace: Analysts Say New Highs Are Coming
Uncertainty Creates Opportunity for Tyson Foods Investors
By Thomas Hughes | May 6, 2025
View Uncertainty Creates Opportunity for Tyson Foods Investors

OVID, CRVO, SNTI, and TCRX Company Descriptions

CervoMed NASDAQ:CRVO

$8.44 -0.46 (-5.17%)

As of 05/9/2025 03:58 PM Eastern

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Ovid Therapeutics NASDAQ:OVID

$0.29 0.00 (-1.33%)

As of 05/9/2025 04:00 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Senti Biosciences NASDAQ:SNTI

$3.35 +0.04 (+1.21%)

As of 05/9/2025 03:44 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

TScan Therapeutics NASDAQ:TCRX

$1.28 -0.10 (-6.88%)

As of 05/9/2025 03:52 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time